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Abstract
Early detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and diagnosis of coronavirus disease 2019 (COVID-19) are priorities 
during the pandemic. Symptomatic and suspected asymptomatic individuals should be tested for COVID-19 to confirm infection and to be excluded 
from social interactions. As molecular testing capacity is overloaded during the pandemic, rapid antigen tests, such as lateral flow immunoassays 
(LFIAs), can be a useful tool as they allow greater test availability and obtain results in a very short time. This short review aims to present the 
analytical properties of LFIAs in the detection of SARS-CoV-2 in nasopharyngeal swabs.
Lateral flow immunoassay is a method that combines thin-layer chromatography and indirect immunochemical sandwich method and allows the 
detection of a specific SARS-CoV-2 antigen in nasopharyngeal swabs. Swab specimens should be adequately collected and tested as soon as possi-
ble. Users should pay attention to quality control and possible interferences. Antigen tests for SARS-CoV-2 show high sensitivity and specificity in ca-
ses with high viral loads, and should be used up to five days after the onset of the first symptoms of COVID-19. False positive results may be obtained 
when screening large populations with a low prevalence of COVID-19 infection, while false negative results may happen due to improper specimen 
collection or insufficient amount of antigen in the specimen. So as to achieve reliable results, a diagnostic accuracy study of a specific rapid antigen 
test should be performed.
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Introduction
Since the outbreak of the coronavirus disease 2019 
(COVID-19) pandemic, clinicians and laboratory sci-
entists have been struggling to reveal the most 
appropriate methods for early diagnosis of the dis-
ease. COVID-19 is caused by severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2), a ribo-
nucleic acid (RNA) virus that first appeared in Wu-
han, China, in late 2019 (1,2). SARS-CoV-2 mainly 
affects the respiratory tract, which can present as 
mild symptoms or progress into severe complica-
tions that can be fatal. For example, it may mani-
fest as acute pulmonary infection, coagulation dis-
orders or gastrointestinal symptoms (most com-
monly diarrhea and nausea) (3-5). SARS-CoV-2 
spreads easily among people who are in close con-
tact. Close contact is defined as being within 1.83 
m of an infected person for a cumulative total of 
15 minutes or more over a 24-hour period (6,7). 
Symptoms (fever, headache, cough, indigestion) 
may appear as early as 5-6 days and as long as 14 
days after possible exposure to the virus (8). Symp-
tomatic and asymptomatic persons who have 
been in close contact with COVID-19 positive or 
suspected persons should be tested for COVID-19 
to confirm transmission and existing infection (9). 
Asymptomatic individuals are considered silent 
transmitters, and those who have had no contact 
or are unaware that they have been in contact 
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with a COVID-19 positive person are particularly 
important (10). Given the problem of silent trans-
mission and the lack of conscious contacts, there is 
a need for screening tests that could indicate posi-
tive asymptomatic individuals who should be ex-
cluded from social interactions.
Currently, there are two types of diagnostic tests 
for detection of SARS-CoV-2 in the nasopharynx of 
infected individuals that indicate COVID-19. First 
and foremost are molecular tests that detect viral 
RNA sequences by nucleic acid amplification tests 
(NAAT), such as real-time reverse transcriptase-
polymerase chain reaction (RT-PCR). This method 
is the gold standard for the detection of SARS-
CoV-2, and results can later be confirmed by an-
other NAAT assay or viral sequencing (11,12). Given 
the increasing number of COVID-19 cases and the 
urgent need to expand the capacity for COVID-19 
testing during public health emergencies, there is 
a strong urge for cheaper, faster, and easier-to-use 
tests that could be used as screening or diagnostic 
tests for COVID-19 in broader populations. There-
fore, another type of diagnostic test has recently 
been introduced, namely the lateral flow immuno-
assay (LFIA), which can detect the presence of spe-
cific viral antigens, i.e., the spike (S) protein or the 
nucleocapsid (N) protein (13). These antigen tests 
aim to rapidly confirm the presence of SARS-CoV-2 
in the nasopharyngeal swab of individuals with 
typical symptoms, as well as to carry out screening 
in a given population for epidemiological purpos-
es, i.e., to determine how much the virus has 
spread in a community. In general, LFIAs provide 
the best information when a person is tested at 
the time of peak viral load and when exposure to a 
person with COVID-19 is known (9).
The first antigen test to receive Emergency Use 
Authorization (EUA) from the US Food and Drug 
Administration (FDA) on March 21, 2020 was the 
Cepheid Xpert Xpress SARS-CoV-2 test (14). Cur-
rently, more than 100 antigen tests are available 
for the detection of SARS-CoV-2 (15).
Lateral flow immunoassays have many advantag-
es, such as relative ease of manufacture, ease of 
use, stability, and use of small sample volumes. 
One of the most appreciated advantages is that 
they are relatively inexpensive, making them avail-
able in many laboratories (16). On the other hand, 
there are also limitations in the performance of 
commonly used LFIAs, especially in terms of ana-
lytical sensitivity and test-to-test reproducibility. 
Test sensitivity may differ in terms of various anti-
gen testing platforms. Laboratories should be 
aware of which platform is being used and the 
sensitivity of the test for the population being 
tested (17). For the interpretation of diagnostic 
tests, it is mandatory to have data on both their 
analytical and clinical sensitivity and specificity. 
Certainly, a prerequisite for diagnostic accuracy 
and reliability of diagnostic tests is their analytical 
accuracy and precision. The final clinical interpre-
tation of antigen testing should include informa-
tion on the presence of symptoms typical of COV-
ID-19 and whether the patient has been in contact 
with a COVID-19 positive person.
In addition, COVID-19 patients could also be tested 
serologically for the detection of antibodies to 
SARS-CoV-2 (11,18). However, the clinical indica-
tions for serological testing and its analytical and 
clinical performance remain limited (18). Because 
seroconversion usually occurs two weeks after the 
onset of symptoms, serological testing should not 
be used as a diagnostic tool for acute COVID-19. 
Furthermore, the presence of SARS-CoV-2 anti-
bodies does not indicate immunity to reinfection, 
but neutralization assays are needed (18).
This review aims to present the basic characteristics 
of LFIAs in the detection of SARS-CoV-2 in naso-
pharyngeal swabs during the COVID-19 pandemic 
from an analytical point of view, including the char-
acteristics and requirements of the preanalytical, 
analytical, and post-analytical phases of the assay.
Preanalytical phase
Indication
The indication for LFIA is made depending on 
whether the patient tested is a person with severe 
symptoms of disease, an asymptomatic person 
who has been in close contact with the patient, or 
an asymptomatic person who is not aware that he 
or she has been in contact with an infected person 
(Figure 1) (9).
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Figure 1. Antigen testing protocol and interpretation of results of infection with SARS-CoV-2: A) in a person with symptoms of dis-
ease; B) in an asymptomatic person who was in close contact with a COVID-19 positive person; C) in an asymptomatic person who 
was in unknown contact with a COVID-19 positive person. Adapted according to the reference (9). SARS-CoV-2 - severe acute respira-





In addition, the result of the detection of SARS-
CoV-2 in the nasopharyngeal swab depends on 
the clinical presentation, the anamnestic data of 
the individual and the time that has elapsed since 
contact with the infected person or patient. In 
most cases of patients with marked symptoms of 
disease, the result will be positive (9). Approxi-
mately seven days after the onset of symptoms, 
the amount of virus in the nose decreases, and af-
ter that period antigen tests may not confirm the 
presence of the virus (9,19). It is recommended to 
use antigen tests within five days of the onset of 
the disease (20). Despite the high specificity of an-
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cially when they are used in communities with low 
prevalence of infection.
Nasopharyngeal swab sampling
Proper performance of nasopharyngeal sampling 
procedure requires competent and well-educated 
personnel (e.g., nurses and technicians) who 
should be trained to always follow the same speci-
men collection steps. The patient’s head should 
be angled back approximately 70 degrees and the 
swab should be inserted perpendicular to the ear 
without lifting the swab so that it deeply contacts 
the nasopharyngeal wall. The swab should be ro-
tated and rubbed against the nasopharyngeal wall 
(clockwise three to five times) and pulled out with 
circular motions to ensure that the absorbent tip 
of the swab is adequately saturated. Only if satura-
tion is not satisfactory for any reason, such as diffi-
cult access due to blocked canals or septal devia-
tion, should swabs be taken from both nostrils 
(21,22).
Specimen handling and transport
Specimen handling is crucial in order to obtain a 
reliable result. Improper procedures can cause 
contamination of the sample. Specimens should 
be tested as soon as possible after collection (9). If 
previous is not possible, the sample is placed in a 
transport medium (with stirring for 15 seconds) 
and delivered promptly to the laboratory. Another 
important step in specimen handling after swab-
bing a potentially infected person is to handle the 
used materials as any other biohazardous materi-
als in the laboratory (23).
Specimen handling, storage, and transport should 
be in accordance with the antigen test manufac-
turer’s instructions. Specimens are transported in 
special transport tubes that must be filled with 2-3 
mL of liquid transport medium so that the absor-
bent tips are completely submerged. The most 
commonly used transport medium is viral trans-
port medium (VTM). Viral transport medium con-
tains the appropriate ingredients selected to cre-
ate an isotonic solution, such as proteins required 
to protect the viral structure, antibiotics to control 
microbial contamination, and one or more buffers 
to control pH. Various VTMs are commercially 
available or can be prepared locally. The purpose 
of VTM is to provide appropriate temperature, pH, 
and nutrient conditions so that viability of the vi-
rus is maintained during storage or transport and 
drying of the sample is prevented. The applicabili-
ty of VTM can be verified by culture isolation or di-
rectly by immunoassay (24). However, phosphate 
buffered saline (PBS), minimum essential media 
(MEM), or sterile saline also proved to be good op-
tions in the absence of standard VTM, as these so-
lutions showed no loss of detection ability during 
antigen testing in seven-day period, whether re-
frigerated or frozen (25,26). Certain VTM formula-
tions ensure inactivation of SARS-CoV-2 virus in 
only a few minutes (27). Only if the sample is test-
ed immediately, it should not be placed in buffers 
or reagents (22,28). During transport, specimens 
should be wrapped with cold packs that maintain 
a temperature of 2-8 °C. Throughout transport, the 
packaging should maintain its integrity (23). Test-
ing of specimens, that have been stored at 2-8 °C, 
should be performed within 72 hours of specimen 
collection (29).
Analytical phase
Principle of the analytical method
Lateral flow immunoassay is a qualitative point-of-
care (POC) method that combines the principles of 
thin-layer chromatography and indirect immuno-
chemical sandwich method with two antibodies, 
i.e., binding and detection antibodies (30). The sta-
tionary phase consists of a thin layer of adsorbent 
material (chromatographic paper or polymer) lo-
cated on a flat, inert substrate. The binding anti-
body was immobilized on the chromatographic 
paper in a specific matrix, while the detection anti-
body labelled with colloidal gold was infiltrated 
into the sample pad. The mobile phase consists of 
a sample and buffer moving horizontally along 
the stationary phase, driven by capillary forces. 
When a sample is applied to the pad, the analyte 
forms an immune complex with the detection an-
tibody labelled with colloidal gold. The sample 
moves laterally and forms a sandwich with the 
binding antibody. After a period of time, a col-
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oured line forms at the site of the equivalence 
zone. The appearance of a coloured line indicates 
the presence of a targeted analyte in the sample. 
The appearance of a control line indicates that the 
analysis was performed properly (31). Tests from 
different manufacturers have different test perfor-
mances and therefore different reading times. 
Most of the tests return results after 15 minutes. 
Test results should be read and interpreted at a 
specific time and not after the time manufacturer 
prescribed (32). 
Although current LFIAs can detect either viral S or 
N antigens, the EUA and FDA have approved as-
says for the detection of N antigens (13). The anti-
gen test result is expressed qualitatively, as posi-
tive or negative.
Limit of detection
The limit of detection (LOD) of a method can be 
defined as the smallest amount of a substance 
that can be detected with reasonable certainty by 
a given analytical procedure (33). The LOD for N 
proteins ranges from 1.0 x 102 TCID50/mL (TCID50 = 
fifty-percent-tissue-culture-infective-dose) to 4.5 x 
105 TCID50/mL. Lateral flow immunoassays cannot 
be used as the sole criterion for the detection of 
SARS-CoV-2 infection. Certainly, the positive result 
can only indicate the presence of viral N antigens 
in the sample, and the result can only be consid-
ered in the context of the patient’s clinical findings 
and other laboratory findings (13). False negative 
results may occur when the concentration of the 
target antigen in the clinical specimen is below 
the LOD value.
Quality control 
An internal control is already installed and includ-
ed in the test device. It is represented by a col-
oured line in the control area. The appearance of 
the procedural control line indicates that sufficient 
flow has occurred and that the functional integrity 
of the test device has been maintained. If the pro-
cedural control line does not develop, the test re-
sult is considered invalid and retesting with a new 
device is recommended. However, internal con-
trols do not evaluate proper sampling technique. 
Positive and negative external control swabs, usu-
ally included in the kit, should be run once with 
each new lot, shipment, and by each new user (32). 
If the coloured line appears only within the control 
region, the result is negative. For the most antigen 
tests, the manufacturer’s instructions state that 
negative test results should be considered “pre-
sumptive”. This means that, in this case, the results 
are preliminary and the negative result should be 
verified by RT-PCR, especially if the person is show-
ing any symptoms or has been in contact with a 
COVID-19 positive person. If the coloured line does 
not appear in the control area, the result should 
not be considered valid. If the control result is in-
valid, the antigen test must be repeated and such 
results must not be reported (9,32).
Interferences
Interference can be defined as the effect of sub-
stances present in an analytical system that cause 
deviation of the measured value from the true val-
ue (34). Although interferences can affect the final 
results, especially in quantitative immunochemical 
methods, interferences can also manifest in quali-
tative immunoassays. Manufacturers of LFIAs for 
the detection of SARS-CoV-2 in nasopharyngeal 
swabs declared cross-reactivity of other viruses, 
bacteria, or yeasts (Candida albicans, 1 x 106 TCID50/
mL) and determined their cut-off values leading to 
possible interferences. A high dose hook effect 
may occur if the tested samples contain a concen-
tration of SARS-CoV-2 virus higher than 1.6 x 105 
TCID50/mL (Table 1) (35).
Some substances that can be found in a patient’s 
nose may also cause cross-reactive reactions: phe-
nylephrine, sodium chloride nasal gel, cromolyn, 
oxymetazoline, fluconazole, throat lozenge (ben-
zocaine, menthol), fluticasone propionate, sore 
throat phenol spray (phenol), the antiviral drug 
Tamiflu (oseltamivir phosphate), mupirocin (antibi-
otic-nasal ointment), and tobramycin (antibacteri-
al-systemic) (35).
Other limitations include the biotin interference 
aspect. Biotin levels of 2.5 µg/mL showed the in-
terference and granted the false negative test re-
sults (32).
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Limitations
The test manufacturers warn of limitations of the 
LFIA which are important to consider when inter-
preting the results obtained. Some of these are: (i) 
a negative result occurs if the amount of antigen 
in a specimen is below the LOD of the test; (ii) un-
reliable results may appear when specimens are 
tested 1 hour after collection; (iii) the test detects 
both viable and non-viable SARS-CoV, and SARS-
CoV-2; (iv) a positive result does not differentiate 
between SARS-CoV and SARS-CoV-2 (35).
Postanalytical phase
Clinical application and interpretation 
A positive LFIA result in an individual who meets 
the clinical and epidemiological criteria for COV-
ID-19 is considered sufficient to confirm the diag-
nosis of the disease. The obtained results, either 
positive or negative, must be entered into a sepa-
rate information system platform that records only 
the results of LFIAs and not the results of molecu-
lar testing (20).
False positive results should be expected while 
screening large populations with a low prevalence 
of COVID-19 infection. A low prevalence is consid-
ered to exist if NAAT positivity in the past 14 days 
is less than 5% or if there are fewer than 20 new 
cases of COVID-19 per 100,000 persons within the 
past 14 days (9). In general, the lower the preva-
lence of infection in the community, the higher is 
the rate of false positive test results (36). False posi-
tive results can also be obtained due to cross-reac-
tivity with the microorganisms containing N anti-
gen, but also as a result of local application of 
drugs and preparations (35).
False negative results may be an outcome of im-
proper sample collection if the amount of antigen 
in the sample is insufficient (9,22).
Comparison of rapid antigen tests with molecular 
methods for virus detection in nasopharyngeal 
Potential reactants Potential reactants
Viruses
Cut-off: 1 x 105 TCID50/mL
Bacteria
Cut-off: 1 x 106 TCID50/mL
Human coronavirus OC43 Bordetella pertusis
Human coronavirus 229E Chlamydia pneumoniae
Human coronavirus NL63 Haemophilus influenzae
Rhinovirus Legionella pneumophila
Adenovirus Streptococcus pneumoniae
Human metapneumovirus Streptococcus pyogenes (Group A)
Human parainfluenza virus 1 Mycobacterium tuberculosis
Human parainfluenza virus 2 Staphylococcus aureus
Human parainfluenza virus 3 Staphylococcus epidermidis





Adapted according to the reference (35). SARS-CoV-2 - severe acute respiratory syndrome 
coronavirus 2. TCID50 - fifty-percent-tissue-culture-infective-dose. 
Table 1. Possible interferences of viruses and bacteria in SARS-CoV-2 detection 
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swabs showed that antigen tests have lower sensi-
tivity due to false negative results. This means that 
antigen tests should not be used as a frontline test 
for COVID-19 diagnosis (37).
In general, the sensitivity of antigen tests is lower 
than RT-PCR. Compared with RT-PCR, the first anti-
gen tests that have received FDA/EUA approval 
have been shown to have a sensitivity of 80% to 
97%, and the specificity is 100% (38). Recently 
published work showed that the accuracy of the 
Roche SARS-CoV-2 rapid antigen test compared 
with the molecular testing was 86.9%, while the 
sensitivity and specificity were 72.5% and 99.4%, 
respectively. In addition, the sensitivity was much 
higher (97-100%) in samples tested with cycle 
threshold (Ct) values of < 25 than in samples with 
Ct values between 30 and 37 (12-18%), proving 
that this test is reliable for the patients with a high 
viral load (39).
Antigen levels in specimens obtained later than 
5-7 days after the first onset of symptoms may fall 
below the detection limit of the test. For this rea-
son, the result may be falsely negative, whereas a 
more sensitive test, such as RT-PCR, may give a 
positive result (9). Since there is still no gold stand-
ard in antigen testing, the respective institutions 
report the analytical accuracy of the diagnostic 
tests they use by comparing them with validated 
tests. Further studies are needed to discern the 
overall performance of antigen tests (40).
It is recommended that the performance of anti-
gen tests is validated in comparison with NAAT 
(12,41). Two respiratory swabs should be collected 
from each participant (within the first seven days 
of symptoms onset), one for molecular analysis 
and diagnosis and another for antigen testing. 
One swab may be sufficient if the buffer/transport 
medium is suitable for both methods. A minimum 
of 100 COVID-19 RT-PCR positives and 100 COV-
ID-19 RT-PCR negatives should be included in the 
study. A sensitivity of 90% or greater and a mini-
mum specificity of 97% are recommended (41). 
Antigen tests with acceptable performance can be 
included in a diagnostic algorithm to reduce the 
need for molecular testing (12).
Antigen tests showed high sensitivity and specific-
ity in respiratory specimens from patients who 
were more symptomatic during the first week of 
infection with COVID-19 (42,43). The sensitivity of 
antigen tests is usually lower than RT-PCR, thus, 
negative antigen tests should be considered pre-
sumptive (9,17,32). Factors that increase the proba-
bility of confirming infection include the presence 
of symptoms in the person tested and recent ex-
posure to a person diagnosed with COVID-19 (17). 
Tests on asymptomatic individuals have more false 
negative results than those on symptomatic indi-
viduals, which is only one limitation of antigen 
testing. Another limitation of antigen testing is 
that they deliver only a qualitative test, which does 
not provide insight into the viral concentration 
present in the sample. Furthermore, the preva-
lence of infection affects the predictive values of 
the antigen test. The positive and negative predic-
tive values are significantly affected by disease 
prevalence. During peak activity, when disease 
prevalence is high, false negative test results are 
more likely. In contrast, during the period of low 
SARS-CoV-2 activity, while prevalence is moderate 
to low, there is a greater possibility of false positive 
test results (32).
In order to interpret the results correctly, several 
things should be considered, such as the perfor-
mance characteristics of the antigen tests, the 
manufacturer’s instructions for use of the specific 
antigen test, and the prevalence of SARS-CoV-2 in-
fection in the community. In addition, the clinical 
and epidemiological context of the person being 
tested must be recorded (9). Antigen tests provide 
the best results in cases with high viral loads, in 
pre-symptomatic and early symptomatic cases up 
to five days after the onset of the first symptoms 
(41). Since most approved antigen tests have high 
sensitivity and specificity, a positive result may be 
considered sufficient to confirm infection in symp-
tomatic or contact-positive individuals, whereas 
RT-PCR should be performed in asymptomatic in-
dividuals and those without known viral exposure.
Concluding remarks
During the COVID-19 pandemic, a central role in 
the health care system was given to the laboratory 
medicine. Lateral flow immunoassays are used in 
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countries or areas where there is widespread pop-
ulation transmission, where the health care system 
may be overburdened, and where it is not feasible 
to test all or suspected cases by NAATs. Antigen 
testing has a major importance in the manage-
ment of spreading COVID-19 infection in commu-
nities with high prevalence of SARS-CoV-2. 
Despite anticipated limitations, LFIAs could play 
an important role in guiding patient management, 
public health decision making, and COVID-19 sur-
veillance. There is a need to identify individuals 
with positive results as soon as possible to prevent 
further transmission of the virus through their self-
isolation. Lateral flow immunoassays allow testing 
of a large number of individuals and obtaining a 
result in a short time and therefore have some ad-
vantage over RT-PCR. However, given the limita-
tions of antigen tests, they cannot yet replace RT-
PCR. 
There is still little data in the literature on both the 
analytical and diagnostic validation of LFIA in the 
detection of SARS-CoV-2 in nasopharyngeal 
swabs. Furthermore, it could be assumed that 
without analytical accuracy of these rapid antigen 
tests, there is also no diagnostic accuracy and reli-
ability. Future research is needed to further im-
prove the analytical sensitivity and specificity of 
these rapid antigen tests so that the results can be 
compared to more expensive and complex molec-
ular diagnostic tests.
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